Gastroenterology
Eupraxia Pharmaceuticals Inc. focuses its clinical research on eosinophilic esophagitis, a chronic inflammatory disorder affecting the esophagus and swallowing function.
- Eosinophilic esophagitis
- Esophageal inflammation
- Swallowing-related disease burden
The sponsor’s research activity is centered on an adult population with symptomatic esophageal disease and histologic measures of tissue involvement.
Inflammatory and Immune-Mediated Disease
The company’s trial portfolio addresses a condition driven by eosinophilic inflammation and local immune activity in the upper gastrointestinal tract.
- Immune-mediated esophageal disease
- Eosinophil-associated inflammation
- Tissue remodeling
Research interest is directed toward disease severity, extent of mucosal involvement, and related inflammatory pathology.
Clinical Pharmacology
Current studies include evaluation of EP 104GI with emphasis on its safety, tolerability, and pharmacokinetic profile in adults.
- Safety and tolerability
- Pharmacokinetics
- Regimen optimization
This area reflects interest in defining how the investigational therapy behaves in the body and how it may be used in esophageal inflammatory disease.
Histology-Based Disease Assessment
The sponsor’s research also involves outcomes tied to histologic scoring of eosinophilic esophagitis, linking treatment evaluation to microscopic tissue change.
- EoE Histology Scoring System
- Mucosal severity
- Extent of disease
These measures place emphasis on objective assessment of inflammation and tissue involvement within the esophagus.
